Company news

Certara, Inc. news in 2022

Certara, Inc.'s news releases, calls and decks from 2022, newest first.

View company

Certara Announces the Completion of Arsenal Capital Partners’ Investment and the Appointment of David Spaight to the Board of Directors

December 7, 2022

Certara Reports Third Quarter 2022 Financial Results

November 6, 2022

Japan’s Pharmaceuticals and Medical Devices Agency (PMDA) Renews Licenses of Certara’s Software for Evaluating Regulatory Submissions

October 18, 2022

Certara to Report Third Quarter 2022 Financial Results on November 7th, 2022

October 12, 2022

Certara Announces Secondary Offering

August 10, 2022

Certara Reports Second Quarter 2022 Financial Results

August 8, 2022

Certara Introduces Update of Pinnacle 21™ Enterprise and New Pinnacle 21™ Data Exchange Module

August 4, 2022

Certara Announces Collaboration with Leading Cancer Center to Advance CAR T-cell Therapies

July 27, 2022

Certara Appoints Rosemary Crane as New Independent Board Member

July 24, 2022

Certara Appoints Eran Broshy as New Independent Board Member

July 12, 2022

Certara to Report Second Quarter 2022 Financial Results on August 9th, 2022

July 11, 2022

Certara Introduces New Simcyp™ Discovery Simulator for Early-Stage and Translational Drug Development

June 27, 2022

Certara Announces New Versions of Biosimulation Software for Development of Novel Biologics

June 20, 2022

Certara Reports First Quarter 2022 Financial Results

May 4, 2022

Certara to Report First Quarter 2022 Financial Results on May 5th, 2022

April 19, 2022

Certara Reports Fourth Quarter and Full Year 2021 Financial Results

February 28, 2022

U.S. FDA Licenses Certara’s Immunogenicity Simulator

February 22, 2022

Certara Customers Received 90 Percent of US FDA Novel Drug Approvals for 8th Consecutive Year

February 14, 2022

Certara to Report Fourth Quarter and Full Year 2021 Financial Results on March 1st, 2022

February 7, 2022

Calls in 2022

Decks in 2022